You recently called out GILD as a good buy. I owned GILD for part of last year but then sold it after examining their earnings growth. I noticed that their HIV business which is large seems to have stagnated. Their HepC business is growing like a weed. I did not examine their pipeline. I ended up selling because of the slow growth in a large portion of their revenue (HIV) and possible competition for their HepC franchise. Did you do a more thorough examination of GILD? In particular, I’m interested to hear what you think about their pipeline and why you think GILD is a good investment now.


1 Like

Hi Chris,

I like GILD for the Hep C opportunity and the relatively cheap valuation. They also have a long list of things in the pipeline although I haven’t done any specific analysis on the pipeline.